Ginsenoside Rg1 Attenuates Neuroinflammation in Parkinson's Disease Models via Concomitant Modulation of Canonical and Noncanonical Wnt Pathways in Microglial M1/M2 Polarization.
Aug 2026· Journal of Agricultural and Food Chemistry· Vol 74 32, pp.
25252-25271
· 0 citations· 57 references
Medicine
TL;DR
Ginsenoside Rg1 alleviates neuroinflammation by recalibrating Wnt signals, offering a potential strategy for PD intervention.
Abstract
Microglial-mediated neuroinflammation is a core driver of brain disorders. Thus, modulating microglial activity is a critical therapeutic goal. In this study, we explored how Ginsenoside Rg1 (Rg1) protects against the inflammation seen in Parkinson's disease (PD). Our experiments utilized MPTP-challenged mice and lipopolysaccharide (LPS)-stimulated BV2 cells. Our data show that Rg1 restores motor function and preserves dopaminergic neurons in the substantia nigra. Notably, Rg1 treatment reconfigures the neuroinflammatory milieu, characterized by the targeted suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and a reciprocal elevation of the anti-inflammatory marker (IL-10). This effect stems from a precise rebalancing of Wnt signaling. Rg1 activates the Wnt3a/β-catenin pathway while suppressing the Wnt5a/ROR2/JNK axis. Such regulation promotes the transition of microglia to a protective M2 phenotype. When we knocked down Wnt3a and ROR2 using siRNA, the benefits of Rg1 were largely lost. In short, Rg1 alleviates neuroinflammation by recalibrating Wnt signals, offering a potential strategy for PD intervention.
The natural flavonoid Astragalin concurrently addresses three core pathological processes in PD, namely dopaminergic neuron degeneration, α-synucleinopathy, and neuroinflammation, through coordinated modulation of interconnected molecular pathways.
Jun Wang, Jie-Yu He, Qin Huang et al.· Free Radical Biology & Medic...· 0 citations
Abstract Background Microglia are central regulators of neuroinflammation in neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). In these conditions, pathological stimuli including lipopolysaccharide (LPS) and amyloid-β (Aβ) peptides promote a phenotypic switch from neuroprotective...
M. Inazu, T. Okada, E. Muto et al.· International Journal of Neu...· 0 citations
Collectively, Simvastatin and Ezetimibe attenuate 3-NP-induced striatal neurodegeneration, possibly through modulation of AMPK/SIRT1-associated neuroinflammatory and glial signaling pathways, warranting further evaluation in additional experimental models.
A. Rezqallah, Eman M. Raafat, Shahira Nofal· Neuropharmacology· 0 citations
Chronic neuroinflammation is implicated in the pathogenesis of Parkinson's disease (PD), contributing to progressive dopaminergic neuron loss. Cobrotoxin (CoTX), a short-chain α-neurotoxin isolated from Naja atra venom, exerts anti-inflammatory and analgesic effects in several inflammation-related disease models. Howev...
Chun-Ze Yu, Shuyang Ma, Yuzhihan Cao et al.· International Immunopharmaco...· 0 citations
GN is a brain-penetrant preclinical candidate that links ATG16L1-dependent autophagy with α-synuclein clearance and NLRP3 inflammasome suppression in PD models and completely abrogated the neuroprotective and anti-inflammatory effects of GN both in vitro and in vivo.
Cheng-Fu Su, Zhi-Qiang Deng, Ka-Yee Ying et al.· Phytomedicine· 0 citations
Parkinson's disease (PD), the world's second most prevalent neurodegenerative disorder, is characterized by midbrain substantia nigra dopaminergic (DA) neuron loss, neuroinflammation, and α-synuclein aggregation. c-Cbl, a RING-finger E3 ubiquitin ligase highly expressed in the substantia nigra and striatum, regulates n...
Chun-Xiao Bai, Xiao-Chuan Qi, An-Heng Zhu et al.· Biochimica et Biophysica Act...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.